Outpatient parenteral antimicrobial therapy (OPAT) practice variation and safety: results of an Emerging Infections Network survey

Michael A. Lane1, Jonas Marschall1, Susan Beekman2, Philip M. Polgreen2, Ritu Banerjee3, Adam L. Hersh4, Hilary M. Babcock1
1Washington University School of Medicine, St. Louis, MO; 2Carver College of Medicine, University of Iowa, Iowa City IA; 3Mayo Clinic, Rochester MN; 4University of Utah, Salt Lake City, UT

Abstract

**Background:** Outpatient parenteral antimicrobial therapy (OPAT) use has been increasing, however little is known about OPAT practice patterns.

**Methods:** In November 2012, we administered an electronic or facsimile survey on OPAT practices to adult infectious disease (ID) physicians participating in the Emerging Infections Network (EIN), a voluntary sentinel event network in North America. Email reminders were sent at 2 and 4 week intervals. The survey consisted of 11 questions on OPAT practices. We obtained demographic characteristics including years in practice, geographic region, employer and primary hospital affiliation type from EIN enrollment data. We analyzed differences in frequencies for statistical significance using χ2 tests, Student’s t-test and Mann-Whitney U-test as appropriate.

**Results:** Overall, 555 (44.6%) of EIN members responded to the survey. Physicians with ≥25 years of experience were the largest group of respondents. Among respondents, 10% (95/951) do not manage OPAT. Of the remaining 450 respondents, most (351; 78%) reported that ID consultation is not required for patients to be discharged on OPAT. Inpatient (322/449, 72%) and outpatient (246/449, 55%) ID physicians were frequently identified as being responsible for monitoring lab results. Only 36% (168/449) had dedicated OPAT teams at their clinical site. The patient’s home was the most common location for patients to receive OPAT. Most ID physicians do not have systems to track errors, adverse events or “near-misses” associated with OPAT (352/449; 78%). OPAT complications were perceived to be rare. Among respondents, 80% (355/448) of respondents report adverse events or harm.

**Conclusions:** Despite widespread use and availability of national guidelines, significant variations exist in OPAT practice. Most institutions do not require ID consultation to initiate OPAT. OPAT complications are perceived to be rare, but few ID physicians have systems to actively track adverse events and harm.

Methods

- The Emerging Infections Network (EIN) is a network of ID physicians in America who provide care to adult and pediatric patients.
- A survey was sent electronically or via facsimile to all members who provide care to adult patients.
- The survey was conducted in November and December 2012. Email reminders were sent to non-respondents 2 and 4 weeks after the initial invitation.
- The survey consisted of brief introductory text and 11 questions.
- Demographic information on respondents including geographic region, years since completing training, employment and hospital type was collected from EIN enrollment data.
- Differences in frequencies were analyzed for statistical significance using χ2 tests, Student’s t-test and Mann-Whitney U-test, as appropriate. A p-value of <0.05 was considered significant.

Results

- 555/1244 (44.6%) physicians participating in EIN responded to the survey.
- Response rates across all US Census regions were similar.
- 450/555 (81%) of respondents discharge patients on OPAT in an average month.
- Most patients receive OPAT in their home (median rank = 1).
- Only 22% (99/550) of respondents indicated ID consultation was required to initiate OPAT.
- Laboratory monitoring is most commonly performed by the inpatient (63%) and outpatient (52%) ID physician.
- 94/450 (21%) indicated the patient’s primary care physician is responsible for monitoring OPAT labs.
- Dedicated OPAT teams are uncommon (118/450, 26%).
- Only 22% (97/450) of respondents have a system to track errors, adverse events, or “near-misses” associated with OPAT.
- Line occlusion, rash and nephrotoxicity are the most commonly reported complications (Figure 1).

Table 1: Laboratory Monitoring Frequency

<table>
<thead>
<tr>
<th>Drug</th>
<th>Total</th>
<th># Weekly</th>
<th># Weekly N (%)</th>
<th># 2x/Week</th>
<th># 3x/Week</th>
<th># 4x/Week</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daptomycin</td>
<td>439</td>
<td>33 (7.5)</td>
<td>388 (87.7)</td>
<td>20 (4.6)</td>
<td>1 (0.2)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>445</td>
<td>16 (3.6)</td>
<td>343 (77.1)</td>
<td>84 (18.9)</td>
<td>2 (0.4)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Daptomycin+V</td>
<td>442</td>
<td>38 (8.6)</td>
<td>385 (87.1)</td>
<td>17 (3.8)</td>
<td>1 (0.2)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Cephalosporins</td>
<td>441</td>
<td>44 (10.0)</td>
<td>384 (87.1)</td>
<td>11 (2.5)</td>
<td>1 (0.2)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Carbapenems</td>
<td>444</td>
<td>44 (9.9)</td>
<td>388 (87.4)</td>
<td>12 (2.7)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Aminoglycosides</td>
<td>435</td>
<td>23 (5.3)</td>
<td>130 (29.9)</td>
<td>247 (56.8)</td>
<td>31 (7.1)</td>
<td>4 (0.9)</td>
</tr>
</tbody>
</table>

**Background**

- Outpatient parenteral antimicrobial therapy (OPAT) has become a common practice for treating a wide range of infections.
- There is significant cost savings by treating patients in the outpatient setting.
- Infectious Disease Society of America (IDSA) guidelines, published in 2004, provides recommendations on appropriate patient selection for OPAT services, antibiotic selection, OPAT team structure, and laboratory monitoring.
- Prior surveys of infectious disease physicians revealed diverse OPAT practice patterns.
- Little is known about OPAT practice patterns, complication rates, and safety systems since the publication of the IDSA guidelines.

**Survey**

- OPAT remains a common approach for treating patients with infections.
- Despite IDSA guidelines recommending appropriate patient selection for OPAT, few organizations require infectious disease consultation prior to discharging patients on OPAT.
- There is tremendous variation in the infrastructure supporting OPAT services; only 26% of respondents report having a dedicated OPAT team to monitor patients’ laboratory results.
- Only 22% of respondents report having a system for tracking clinical outcomes, adverse events, and the safety of OPAT.
- OPAT complications are relatively common. Line occlusion, rash and nephrotoxicity were the most commonly reported complications of OPAT therapy.
- Although clinical guidelines recommend weekly laboratory monitoring in patients treated with vancomycin, these guidelines do not address the safety of high dose vancomycin strategies that target a trough concentration of 15-20 mg/mL. Frequent laboratory monitoring, favored by 19% of respondents, may allow for early identification and intervention in patients who develop nephrotoxicity.
- Standardization of OPAT practices may provide opportunities to improve clinical outcomes and the safety of OPAT.

**Figure 1: Reported Frequency of Complications**

**Figure 2: Reported Outcomes of Complications**

**Figure 3: Change in Therapy**

**Table 1: Laboratory Monitoring Frequency**

**Table 2: Change in Therapy**